Balancing short-term symptom control and long-term functional outcomes in patients with Parkinson's disease

CNS Spectrums

Volumn 12, Issue 4, 2007, Pages 275-286

  Tetrud, James W ^a  

^a PARKINSON S INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; APOMORPHINE; BENZATROPINE; BROMOCRIPTINE; CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; ENTACAPONE; LEVODOPA; MUSCARINIC RECEPTOR BLOCKING AGENT; PERGOLIDE; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOCOPHEROL; TOLCAPONE; TRIHEXYPHENIDYL;

COGNITIVE DEFECT; CONFUSION; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG WITHDRAWAL; DYSKINESIA; HALLUCINATION; HEADACHE; HUMAN; HYPERKINESIA; HYPOKINESIA; HYPOTENSION; INSOMNIA; LEG EDEMA; LIVEDO RETICULARIS; LIVER TOXICITY; LONG TERM CARE; MONOTHERAPY; NAUSEA; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SYMPTOM; UNSPECIFIED SIDE EFFECT; URINE COLOR; YAWNING;

EID: 34248144005     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900021039     Document Type: Review

References (101)

1. National Center for Health Statistics. NCHS data on Parkinson's disease. Available at: http://www.cdc.gov/nchs/data/factsheets/Parkinsons.pdf. 2005. Accessed on July 19, 2006.
2. Tanner CM, Aston DA. Epidemiology of Parkinson's disease and akinetic syndromes. Curr Opin Neurol. 2000;13:427-430.
3. Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med. 1998;339:1044-1053.
4. Guttman M, Kish SJ, Furukawa Y. Current concepts in the diagnosis and management of Parkinson's disease. CMAJ. 2003;168:293-301.
5. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197-211.
6. Colcher A, Simuni T. Clinical manifestations of Parkinson's disease. Med Clin North Am. 1999;83:327-347.
7. Dhawan V, Healy DG, Pal S, Chaudhuri KR. Sleep-related problems of Parkinson's disease. Age Aging. 2006;35:220-228.
8. Koller WC, Tse W. Unmet medical needs in Parkinson's disease. Neurology. 2004;62(suppl 1):S1-S8.
9. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet. 2002;359:1589-1598.
10. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427-442.
11. Koller W, Guarnieri M, Hubble J, Rabinowicz AL, Silver D. An open-label evaluation of the tolerability and safety of Stalevo(carbidopa, levodopa and entacapone)in Parkinson's disease patients experiencing wearing-off. J Neural Transm. 2005;112:221-230.
12. Cohen G, Spina MB. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol. 1989;26:689-690.
13. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol. 2006;59:559-562.
14. Aminoff MJ. Treatment should not be initiated too soon in Parkinson's disease. Ann Neurol. 2006;59:562-564.
15. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351:2498-2508.
16. Thanvi BR, Lo TC. Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. Postgrad Med J. 2004;80:452-458.
17. Adler CH. Relevance of motor complications in Parkinson's disease. Neurology. 2002;58(suppl 1):S51-S56.
18. Muller T, Russ H. Levodopa, motor fluctuations and dyskinesia in Parkinson's disease. Expert Opin Pharmacother. 2006;7:1715-1730.
19. Sato K, Hatano T, Yamashiro K, et al. Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations. Mov Disord. 2006;21:1384-1395.
20. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain. 2000;123(pt 11):2297-2305.
21. Mazzella L, Yahr MD, Marinelli L, Huang N, Moshier E, Di Rocco A. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy. Parkinsonism Relat Disord. 2005;11:151-155.
22. Mccoll CD, Reardon KA, Shiff M, Kempster PA. Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease. Mov Disord. 2002;17:1227-1234.
23. Rajput AH, Fenton ME, Birdi S, et al. Clinical-pathological study of levodopa complications. Mov Disord. 2002;17:289-296.
24. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's desease-clinical aspects. In: Marsden CD, Fahn S, eds. Movement Disorders. Boston, Mass: Butterworth Scientific; 1982:96-122.
25. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448-458.
26. Blanchet PJ, Allard P, Gregoire L, Tardif F, Bedard PJ. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci. 1996;23:189-193.
27. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA. 2000;284:1931-1938.
28. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group. Ann Neurol. 1996;39:37-45.
29. Stacy M, Bowron A, Guttman M, et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord. 2005;20:726-733.
30. Nutt JG, Woodward WR, Carter JH, Gancher ST. Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon. Arch Neurol. 1992;49:1123-1130.
31. Barbato L, Stocchi F, Monge A, et al. The long-duration action of levodopa may be due to a postsynaptic effect. Clin Neuropharmacol. 1997;20:394-401.
32. Nutt JG, Carter JH, Lea ES, Sexton GJ. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol. 2002;51:686-693.
33. Obeso JA, Rodriguez-Oroz M, Marin C, et al. The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology. 2004;62(suppl 1):S17-S30.
34. Metman LV, Konitsiotis S, Chase TN. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Mov Disord. 2000;15:3-8.
35. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5:677-687.
36. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord. 2005;20:224-230.
37. Wilson RE, Silver D, Spears JB, Van Lunen BE. Implications of motor fluctuations in Parkinson's patients on chronic therapy (IMPACT) registry: quality of life (QOL) data. Mov Disord. 2006;21(suppl 1):S151.
38. Bloem BR, Hausdorff JM, Visser JE, Giladi N. Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena. Mov Disord. 2004;19:871-884.
39. Martinez-Martin P, Benito-Leon J, Alonso F, et al. Quality of life of caregivers in Parkinson's disease. Dual Life Res. 2005;14:463-472.
40. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: Frequent and disabling. Neurology. 2002;59:408-413.
41. van Laar T. Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management. CNS Drugs. 2003;17:475-489.
42. Parcopa [package insert]. Milwaukee, Wis: Schwarz Pharma; 2006.
43. Sinemet [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2002.
44. Sinemet CR [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2002.
45. Stalevo [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2004.
46. Apokyn [package insert]. Research Triangle Park, NC: Mylan Bertek Pharmaceuticals, Inc.; 2004.
47. Parlodel Snap Tabs [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corp.; 2006.
48. Permax [package insert]. Indianapolis, Ind: Eli Lilly & Co.; 2001.
49. Mirapex [package insert]. Ridgefield, Conn: Boehringer-Ingelheim International GmbH; 2006.
50. Requip [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2001.
51. Comtan [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2000.
52. Tasmar [package insert]. Costa Mesa, Calif: Valeant Pharmaceuticals International; 2006.
53. Azilect [package insert]. Kansas City, Mo: Teva Pharmaceutical Industries, Ltd.; 2006.
54. Eldepryl [package insert]. Tampa, Fla: Somerset Pharmaceuticals; 1998.
55. Zelapar [package insert]. Costa Mesa, Calif: Valeant Pharmaceuticals International; 2006.
56. Symadine [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corp.; 2006.
57. Symmetrel [package insert]. Princeton, NJ; Bristol-Myers Squibb Company; 2002.
58. Cogentin [package insert]. Whitehouse Station, NJ; Merck & Co., Inc.; 2006.
59. Artane [package insert]. Pearl River, NY: Lederle Pharmaceutical Division; 2003.
60. Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson's disease. Mov Disord. 2005;20:1502-1507.
61. Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology. 1999;53:1012-1019.
62. Dlanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 2001;56(suppl 5):S1-S88.
63. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49:162-168.
64. LeWitt PA, Chang F-L, Fazzini E, Nausieda PA, Daniel T, Boroojerdi B. Rotigotine transdermal system in treatment of patients with advanced-stage Parkinson's disease. Abstract presented at: annual meeting of European Federation of Neurological Societies Congress. September 17-20, 2005; Athens, Greece.
65. Poewe W, Giladi N, Maguire D, Boroojerdi B. Rotigotine transdermal patch in patients with parkinson's disease and motor fluctuations. 24H symptom control in a placebo- and Pramipexole-controlled, randomized, double-blind, double dummy trial. Abstract presented at: annual meeting of European Federation of Neurological Societies Congress. September 2-5, 2006; Glasgow, Scotland.
66. Pahwa R, Factor SA, Elmer LW. Ropinirole 24-hour prolonged release reduces 'off' time in patients with parkinson's disease not optimally controlled with L-Dopa. Abstract presented at: annual meeting of European Federation of Neurological Societies Congress. September 2-5, 2006; Glasgow, Scotland.
67. Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol. 2005;62:1377-1381.
68. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68:272-276.
69. Avorn J, Schneeweiss S, Sudarsky LR, et al. Sudden uncontrollable somnolence and medication use in Parkinson disease. Arch Neurol. 2005;62:1242-1248.
70. Pezzella FR, Colosimo C, Vanacore N, et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord. 2005;20:77-81.
71. Pontone G, Williams JR, Bassett SS, Marsh L. Clinical features associated with impulse control disorders in Parkinson disease. Neurology. 2006;67:1258-1261.
72. Sundberg S, Scheinin M, Illi A, Akkila J, Gordin A, Keranen T. The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise. Br J Clin Pharmacol. 1993;36:451-456.
73. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007;356:39-46.
74. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet. 2004;363:1179-1183.
75. Horvath J, Fross RD, Kleiner-Fisman G, et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord. 2004;19:656-662.
76. Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord. 2004;19:426-432.
77. Stocchi F. Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease. Int J Clin Pract. 2006;60:215-221.
78. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365:947-954
79. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62:241-248.
80. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord. 2005;20:523-539.
81. Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004;75:141-143.
82. Luginger E, Wenning GK, Bosch S, Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord. 2000;15:873-878.
83. Weller M, Kornhuber J. Amantadine withdrawal and neuroleptic malignant syndrome. Neurology. 1993;43:2155.
84. Anticholinergic therapies in the treatment of Parkinson's disease. Mov Disord. 2002;17(suppl 4):S7-S12.
85. Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev. 2003;CD003735.
86. Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology. 2004;62(suppl 1):S56-S63.
87. Adler CH, Singer C, O'Brien C, et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol. 1998;55:1089-1095.
88. Borges N. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy. Drug Saf. 2003;26:743-747.
89. Hauser RA. Levodopa/carbidopa/entacapone (Stalevo), Neurology. 2004;62(suppl 1):S64-S71.
90. Stocchi F, Vacca L, Grassini P, et al. Optimizing levodopa pharmacokinetics in Parkinson's disease: the role of COMT inhibitor. Neurol Sci. 2003;24:217-218.
91. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol. 1997;42:747-755.
92. Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology. 1998;51:1309-1314.
93. Peewe WH, Deuschl G, Gordin A, Kultalahti E-R, Leinonen M. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002;105:245-255.
94. Reichmann H, Boas J, Macmahon D, Myllyla V, Hakala A, Reinikainen K. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand. 2005;111:21-28.
95. Brooks DJ. Safety and tolerability of COMT inhibitors. Neurology. 2004;62(suppl 1):S39-S46.
96. Silver DE. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo). Expert Rev Neurother. 2004;4:589-599.
97. Brooks DJ, Agid Y, Eggert K, Widner H, Ostergaard K, Holopainen A; TC-INIT Study Group. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur Neurol. 2005;53:197-202.
98. Myllyla V, Haapaniemi T, Kaakkola S, et al. Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study). Acta Neurol Scand. 2006;114:181-186.
99. Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol. 2001;58:1385-1392.
100. Zijlmans JC, Debilly B, Rascol O, Lees AJ, Durif F. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study. Mov Disord. 2004;19:1006-1011.
101. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:983-985.